Business Context and Reporting Period
This Form 8-K is filed by Silverback Therapeutics, Inc. (SBTX), an emerging growth company, reporting events occurring on September 27, 2022. The filing addresses a material change to the company's primary executive office lease located at 500 Fairview Avenue North, Seattle, Washington.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a contractual lease amendment and termination rather than financial performance metrics.
Material Changes Versus Prior Period
- Lease Amendment: Entered into a Second Amendment to Lease with BMR-500 Fairview Avenue LLC, extending the lease term to expire on December 31, 2022.
- Lease Termination: Delivered a notice of termination for the same lease, effective December 31, 2022.
- Contingency: The amendment was contingent upon the execution of a new lease with a different tenant, which was completed on September 27, 2022.
- Cost Impact: No termination fee is required to be paid to the Landlord.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of general business risks. The primary operational implication is the scheduled vacating of the current premises by the end of 2022, with the company remaining responsible for rent until the expiration date.
Investor Verification Checklist
- Verify the terms of the new lease executed by the incoming tenant to ensure the termination of Silverback's lease is fully secured.
- Confirm the exact move-out date and any potential costs associated with relocating operations prior to December 31, 2022.
- Review the company's cash position in subsequent filings to assess the impact of rent obligations through the end of the year.